VRAS (Velys Robot-Assisted Solution) Operational Excellence Study
Launched by DEO NV · Aug 20, 2024
Trial Information
Current as of September 08, 2025
Recruiting
Keywords
ClinConnect Summary
The VRAS (Velys Robot-Assisted Solution) Operational Excellence Study is a clinical trial designed to explore how using a robotic system for knee replacement surgery (known as Total Knee Arthroplasty or TKA) compares to traditional methods. The study will look at various aspects, such as how efficiently the surgery is set up, the workload of the operating room team, and the overall financial performance of the procedures. This could help us understand if the robotic approach offers any significant benefits.
To participate in this study, orthopedic surgeons who perform both conventional and robot-assisted knee surgeries are eligible. While this trial is currently recruiting, it doesn’t involve direct participation from patients. Instead, the focus is on the surgeons and how they perform these surgeries. If you or a family member are considering knee replacement surgery, it’s worth noting that advancements like robotic assistance may improve the overall experience and outcomes in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Orthopaedic surgeons performing conventional and robot-assisted TKA
- Exclusion Criteria:
- • /
About Deo Nv
Deo NV is a leading clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a robust portfolio of clinical studies, Deo NV focuses on therapeutic areas that address unmet medical needs, leveraging cutting-edge technology and methodologies to ensure the highest standards of participant safety and data integrity. Committed to collaboration with healthcare professionals and regulatory bodies, Deo NV strives to accelerate the timeline for bringing new treatments to market, ultimately improving patient outcomes and enhancing quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, Ng5 8rx, United Kingdom
Nottingham, , United Kingdom
Patients applied
Trial Officials
Willem Franssen, Msc.
Study Director
DEOcare
Benjamin Bloch, M.D.
Principal Investigator
Circle Health Group - BMI The Park Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported